Form 4: CFO Vaseem Mahboob Receives Kestra Medical Equity Grant

Kestra Medical Technologies CFO Vaseem Mahboob was granted 25,227 restricted stock units as part of a three-year vesting plan.

Summary

• Vaseem Mahboob, Chief Financial Officer of Kestra Medical Technologies, Ltd., acquired 25,227 restricted stock units (RSUs) on June 3, 2026.
• The RSUs vest over a three-year period, with one-third of the units vesting on each anniversary of the grant date, contingent upon continued service.
• Following this transaction, the reporting person's total beneficial ownership increased to 67,961 common shares.
• The total includes 5,837 shares received via a pro rata distribution from West Affum Holdings, L.P.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through a three-year RSU vesting schedule.
• Increase in total beneficial ownership by the CFO, signaling confidence in the company's future.

Negatives

• None identified in this filing.

Risks

• Vesting of equity is subject to the reporting person's continued service to the company.

Future Outlook

The RSUs are subject to a three-year vesting schedule, with 1/3 vesting annually starting June 3, 2027, provided the reporting person remains in service.

Industry Context

StockSavvy.ai notes that equity-based compensation for C-suite executives is a standard industry practice to ensure management retention and alignment with corporate performance goals.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard corporate governance practices for executive compensation in the medical technology sector.
• The use of RSUs as a retention tool is common among mid-cap and growth-stage medical device companies.

Related Party Transactions

• The reporting person received 5,837 common shares from West Affum Holdings, L.P. in a pro rata distribution.

Stakeholder Impact

• Shareholders may view the increased equity stake of the CFO as a positive sign of management commitment.

Next Steps

• Vesting of the first tranche of 1/3 of the RSUs on June 3, 2027.

Key Dates

Keywords

Kestra Medical Technologies, KMTS, Form 4, Insider Trading, Equity Compensation, CFO